Michael Conick Hanley Jr., Chief Operating Officer of Alto Neuroscience, Inc. (NASDAQ:ANRO), filed a Form 4 on November 18, 2026, disclosing option exercises and open-market sales of common stock occurring on November 16, 17, and 18, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Trading plan in effect: All transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Hanley on August 14, 2026.
- Options exercised at $2.35: Across the three-day period, Hanley exercised employee stock options covering a total of 77,000 shares of common stock at an exercise price of $2.35 per share.
- Shares sold on November 16: 56,410 shares were sold at a weighted average price of $27.463 (range $26.95 to $27.94), 10,895 shares at a weighted average of $28.4265 (range $27.95 to $28.91), and 2,695 shares at a weighted average of $29.0863 (range $28.95 to $29.17).
- Shares sold on November 17: 2,104 shares were sold at $26.816.
- Shares sold on November 18: 2,896 shares were sold at $26.48.
- Beneficial ownership following transactions: Hanley reported 0 shares of common stock directly owned following the final transactions on each respective date, with 165,271 employee stock options remaining under one grant.
Hanley's Option Exercises and Sales Across Three Days at Alto Neuroscience
According to the filing, Hanley exercised five tranches of employee stock options and sold all resulting shares between November 16 and November 18, 2026. The transactions covered three separate option grants, each carrying an exercise price of $2.35 per share. On November 16, he exercised 17,729 options expiring May 19, 2034; 44,271 options expiring February 4, 2035; and 8,000 options expiring February 28, 2034. On November 17, he exercised an additional 2,104 options from the May 19, 2034 grant, and on November 18 he exercised 2,896 more from the same grant.
The filing notes that the 8,000-share option grant is "fully vested and exercisable." For the May 19, 2034 expiry grant, the filing states that 25% of the underlying shares vested on May 20, 2025, with one forty-eighth (1/48th) vesting in monthly installments thereafter. For the February 4, 2035 expiry grant, 25% vested on February 5, 2026, with one forty-eighth (1/48th) vesting monthly thereafter, in each case subject to continuous service. Following the November 16 exercises, the filing reports remaining unexercised balances of 170,271, 80,729, and 0 options on those three grants, respectively, with subsequent exercises reducing the first grant to 165,271 by November 18.
The November 16 sales were executed in multiple transactions across three price ranges, and the filing states that weighted average prices are reported. The reporting person has undertaken to provide full per-price transaction detail to the issuer, any security holder, or SEC staff upon request. All transactions are attributed in the filing to the Rule 10b5-1 plan Hanley adopted on August 14, 2026. The form was signed by Erin R. McQuade as Attorney-in-Fact on November 18, 2026.
What Was Disclosed
Alto Neuroscience's COO, Michael Conick Hanley Jr., disclosed the exercise of 77,000 employee stock options at $2.35 and the sale of all resulting shares over November 16-18, 2026, under a pre-established 10b5-1 trading plan adopted August 14, 2026.



Please wait processing your request...